Beta‐blockers, hypertension, and stroke outcomes

Beta‐blockers, hypertension, and stroke outcomes Treatment of high blood pressure remains a cornerstone in stroke prevention, and beta‐blockers have now been used to treat hypertension and prevent strokes for almost 5 decades. The first beta‐blocker to be used in clinical medicine, propranolol, was originally invented to provide relief for patients with angina pectoris. It was specifically designed to block the beta adrenergic receptors of the heart, thus decreasing the myocardial oxygen demand. It was soon found, however, that the newly developed drug could also be used as a blood pressure lowering medication. Placebo‐controlled trials such as the landmark MRC trial demonstrated a reduced risk for stroke in hypertensive patients who used beta‐blockers. Indeed, the clinical usefulness of beta‐blockers led to its inventor, Sir James Black, being awarded with the Nobel Prize in Physiology or Medicine in 1988. However, modern hypertension trials have suggested that at similar attained blood pressure levels, beta‐blockers are actually less effective than angiotensin receptor blockers or calcium channel blockers, in terms of stroke prevention. The same picture has emerged from the most recent meta‐analysis on this topic, in which beta‐blocker use was associated with decreased risk for stroke compared with placebo, but beta‐blocker use was also associated with increased risk http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Hypertension Wiley

Beta‐blockers, hypertension, and stroke outcomes

Loading next page...
 
/lp/wiley/beta-blockers-hypertension-and-stroke-outcomes-YU9wy0yJ6M
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 Wiley Periodicals, Inc.
ISSN
1524-6175
eISSN
1751-7176
D.O.I.
10.1111/jch.13234
Publisher site
See Article on Publisher Site

Abstract

Treatment of high blood pressure remains a cornerstone in stroke prevention, and beta‐blockers have now been used to treat hypertension and prevent strokes for almost 5 decades. The first beta‐blocker to be used in clinical medicine, propranolol, was originally invented to provide relief for patients with angina pectoris. It was specifically designed to block the beta adrenergic receptors of the heart, thus decreasing the myocardial oxygen demand. It was soon found, however, that the newly developed drug could also be used as a blood pressure lowering medication. Placebo‐controlled trials such as the landmark MRC trial demonstrated a reduced risk for stroke in hypertensive patients who used beta‐blockers. Indeed, the clinical usefulness of beta‐blockers led to its inventor, Sir James Black, being awarded with the Nobel Prize in Physiology or Medicine in 1988. However, modern hypertension trials have suggested that at similar attained blood pressure levels, beta‐blockers are actually less effective than angiotensin receptor blockers or calcium channel blockers, in terms of stroke prevention. The same picture has emerged from the most recent meta‐analysis on this topic, in which beta‐blocker use was associated with decreased risk for stroke compared with placebo, but beta‐blocker use was also associated with increased risk

Journal

Journal of Clinical HypertensionWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial